ema

Healthcare professionals’ working party elects co-chair The European Medicines Agency’s (EMA) Healthcare Professionals’ Working Party (HCPWP) has re-elected Prof. Gonzalo Calvo as its co-chair at the September 2016 meeting. Prof. M. de Visser, EAN Treasurer, is the EAN delegate to… Continue Reading

Elena Moro (EM): As incoming co-chair of the Scientific Panel “Neuroimmunology” can you briefly introduce yourself and your specific field of expertise to the EANpages readers? Luca Massacesi (LM): I am a neurologist with special interest in Clinical Immunology. I have been appointed Professor of Neurology at the Department of Neurosciences, University of Florence, Italy, in 2005.

After more than a decade from the natalizumab approval, most MS specialists consider this biological therapy as one of the most efficient drugs that we have nowadays to treat relapsing-remitting MS patients. However, the problem we have to face when we start to use natalizumab is the risk of the occurrence of progressive multifocal leukoencephalopathy (PML) in some patients.

by Anna Sauerbier   Outbreak of Zika Virus Disease – general information The Zika virus and potential neurological effects The European Medicines Agency (EMA) has released a revised guideline on medicines for the treatment of Alzheimer’s disease and other types… Continue Reading

Professor Babro Westerholm is a Swedish Liberal People's Party politician. She has been a member of the Riksdag since 2006. She was previously a member from 1988 to 1999. From the mid 1960s Westerholm was an early pioneer in the field of pharmacovigilance, also working on the early stages of the WHO Drug Dictionary and the WHO Programme for International Drug Monitoring.

by Marianne de Visser The EMA is pleased to announce the launch of the new European database of suspected adverse drug reaction reports website at http://www.adrreports.eu/.
The launch of the website is a positive first step in the implementation of… Continue Reading